OpGen to Provide Business Update and Financial Results for the First Quarter 2020
April 27 2020 - 8:30AM
OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced
today that the Company will provide a business update and report
its first quarter 2020 financial results after the close of the
U.S. financial markets on Thursday, May 7, 2020. OpGen’s management
team will host a live conference call and audio webcast at 4:30
p.m. Eastern Time to discuss the Company’s financial results and
provide an update on business activities.
Conference Call Details |
|
U.S. Dial-in Number: |
+1 (844) 420-8185 |
International Dial-in Number: |
+1 (216) 562-0481 |
Webcast: |
https://edge.media-server.com/mmc/p/iggnmjim |
Conference ID: |
8595009 |
|
|
Reply Details |
|
U.S. Dial-in Number: |
+1 (855) 859-2056 |
International Dial-in Number: |
+1 (404) 537-3406 |
Conference ID: |
8595009 |
Following the conclusion of the conference call,
a replay will be available through May 14, 2020. The live,
listen-only webcast of the conference call may also be accessed by
visiting the Investors section of the Company’s website at
www.opgen.com. A replay of the webcast will be available following
the conclusion of the call and will be archived on the Company’s
website for 90 days.
About OpGen, Inc.
OpGen, Inc. (Gaithersburg, MD, USA) is a
precision medicine company harnessing the power of molecular
diagnostics and bioinformatics to help combat infectious disease.
Along with subsidiaries, Curetis GmbH and Ares Genetics GmbH, OpGen
is developing and commercializing molecular microbiology solutions
helping to guide clinicians with more rapid and actionable
information about life threatening infections to improve patient
outcomes, and decrease the spread of infections caused by
multidrug-resistant microorganisms, or MDROs. OpGen’s product
portfolio includes Unyvero, Acuitas AMR Gene Panel and Acuitas®
Lighthouse, and the ARES Technology Platform including ARESdb,
using NGS technology and AI-powered bioinformatics solutions for
antibiotic response prediction.
For more information, please visit www.opgen.com.
OpGen:Oliver SchachtPresident and
CEOInvestorRelations@opgen.com
OpGen Press Contact:Matthew Bretzius FischTank
Marketing and PRmatt@fischtankpr.com
OpGen Investor Contact:Joe GreenEdison Group
jgreen@edisongroup.com
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Sep 2023 to Sep 2024